- Home
- JRS vs LYEL Comparison
JRS vs LYEL Comparison
Compare JRS & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JRS
- LYEL
- Stock Information
- Founded
- JRS 2001
- LYEL 2018
- Country
- JRS United States
- LYEL United States
- Employees
- JRS N/A
- LYEL N/A
- Industry
- JRS Finance/Investors Services
- LYEL Biotechnology: Pharmaceutical Preparations
- Sector
- JRS Finance
- LYEL Health Care
- Exchange
- JRS Nasdaq
- LYEL Nasdaq
- Market Cap
- JRS 236.9M
- LYEL 207.7M
- IPO Year
- JRS N/A
- LYEL 2021
- Fundamental
- Price
- JRS $8.23
- LYEL $0.54
- Analyst Decision
- JRS
- LYEL Sell
- Analyst Count
- JRS 0
- LYEL 2
- Target Price
- JRS N/A
- LYEL $1.00
- AVG Volume (30 Days)
- JRS 86.6K
- LYEL 866.3K
- Earning Date
- JRS 01-01-0001
- LYEL 03-11-2025
- Dividend Yield
- JRS 8.87%
- LYEL N/A
- EPS Growth
- JRS N/A
- LYEL N/A
- EPS
- JRS N/A
- LYEL N/A
- Revenue
- JRS N/A
- LYEL $61,000.00
- Revenue This Year
- JRS N/A
- LYEL N/A
- Revenue Next Year
- JRS N/A
- LYEL N/A
- P/E Ratio
- JRS N/A
- LYEL N/A
- Revenue Growth
- JRS N/A
- LYEL N/A
- 52 Week Low
- JRS $5.95
- LYEL $0.48
- 52 Week High
- JRS $8.00
- LYEL $3.15
- Technical
- Relative Strength Index (RSI)
- JRS 42.90
- LYEL 43.44
- Support Level
- JRS $8.04
- LYEL $0.53
- Resistance Level
- JRS $8.21
- LYEL $0.63
- Average True Range (ATR)
- JRS 0.11
- LYEL 0.07
- MACD
- JRS -0.00
- LYEL -0.00
- Stochastic Oscillator
- JRS 46.34
- LYEL 26.39
About JRS Nuveen Real Estate Income Fund of Beneficial Interest
Nuveen Real Estate Income Fund is a diversified closed-end investment company. The Fund invests primarily in income-producing common stocks, preferred stocks, convertible preferred stocks, and debt securities issued by real estate companies. At least 75% of the Fund's managed assets will be in securities rated investment grade.
About LYEL Lyell Immunopharma Inc.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.